Only Available By Prescription
Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Fruzaqla (fruquintinib) is an oral, highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor used for the treatment of previously treated metastatic colorectal cancer (mCRC). It targets VEGFR-1, -2, and -3, thereby inhibiting angiogenesis, which is essential for tumor growth and metastasis. Approved by the U.S. FDA in 2023, Fruzaqla is indicated for adult patients who have received prior treatment with standard therapies including fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF therapy, and, if RAS wild-type and appropriate, anti-EGFR therapy. It offers a targeted option with a manageable safety profile and demonstrated efficacy in patients who have progressed on multiple lines of therapy.
| Fact Table | |
| Formula | C21H19ClN4O3 |
| License | US FDA (2023) |
| Bioavailability | ~38% |
| Legal status | Prescription only |
| Chemical Name | Fruquintinib |
| Elimination half-life | 33.4–42.2 hours |
| Dosage (Strength) | 5 mg oral capsules |
| Pregnancy | Not recommended – may cause fetal harm |
| Brands | Fruzaqla |
| Protein binding | ~90% |
| PubChem CID | 49806716 |
| MedlinePlus | a622070 |
| ChEBI | 145328 |
| ATC code | L01EK03 |
| DrugBank | DB12267 |
| KEGG | D10932 |
| Routes of administration | Oral |
Fruzaqla is administered orally at a recommended dose of 5 mg once daily, with or without food, for the first 21 days of each 28-day cycle. Treatment continues until disease progression or unacceptable toxicity. Tablets should be swallowed whole and not crushed or chewed. Dose modifications may be required based on tolerability, laboratory findings, or adverse reactions. Close monitoring of blood pressure, liver function, and proteinuria is recommended during therapy.
Each Fruzaqla tablet contains:
Fruzaqla is contraindicated in patients with:
Fruzaqla may increase the risk of hypertension, hemorrhage, thromboembolic events, gastrointestinal perforation, and hepatotoxicity. Liver function and blood pressure should be assessed before initiating treatment and monitored regularly. Use caution in patients with a history of cardiovascular disease, gastrointestinal disorders, or bleeding diathesis. Effective contraception should be used during treatment and for at least 2 weeks after the last dose. Fruzaqla is not recommended during pregnancy or breastfeeding due to potential harm to the fetus or infant.
Common and potential side effects include:
Exceptional Customer Service
We pride ourselves on delivering excellent customer service with as much accessibility as possible.
If you have any questions at all, or would like to place an order, you are encouraged to contact us by toll-free
phone 1-888-904-8467 or email info@canadadrugsdirect.com.
Top Safety and Quality
Canada Drugs Direct employs dedicated, professional licensed pharmacists to ensure that each and every order is reviewed before it is dispensed for the safety and health of our customers. At CanadaDrugsDirect.com, your health is our top priority.
Product Reviews